Drug news
FDA approves FluLaval Quadrivalent vaccine
GlaxoSmithKline announced that the FDA has approved FluLaval Quadrivalent influenza Virus Vaccine for the active immunization of persons three years of age and older to help prevent disease caused by seasonal Influenza (flu) virus subtypes A and B contained in the vaccine. This is the second GSK intramuscular quadrivalent influenza vaccine approved by the FDA. GSK's Fluarix Quadrivalent was the first-ever intramuscular influenza vaccine approved by the FDA in December 2012 and is now shipping to customers.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins